Targeting Wnt signaling, such as GSK-3β inhibitors, shows promise in mitigating Aβ toxicity and neurodegeneration in preclinical AD models (Avila and Hernández, 2007; Griebel et al., 2019). This evidence concerns the gene GSK3B and Alzheimer disease.